Santarus, Inc. : Santarus to Present at March Investment Conferences
02/29/2012| 04:05am US/Eastern
Recommend:
Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T. Proehl,
president and chief executive officer, will make presentations at the
following investment conferences:
-
Cowen and Company 32nd Annual Health Care Conference on
Wednesday, March 7, 2012, at 10:00 a.m. Eastern time (7:00 a.m.
Pacific time) at the Boston Marriott Copley Place; and
-
Roth Capital Partners 24th Annual Growth Stock Conference
on Monday, March 12, 2012, at 11:30 a.m. Pacific time (2:30 p.m.
Eastern time) at the Ritz Carlton in Dana Point, Calif.
Webcasts of these presentations will be available during the event at www.santarus.com
and will be archived and available on the website for 14 days.
About Santarus
Santarus, Inc. is a specialty biopharmaceutical company focused on
acquiring, developing and commercializing proprietary products that
address the needs of patients treated by physician specialists. The
company's current commercial efforts are focused on GLUMETZA®
(metformin hydrochloride extended release tablets) and CYCLOSET®
(bromocriptine mesylate) tablets, which are indicated as adjuncts to
diet and exercise to improve glycemic control in adults with type 2
diabetes, and on FENOGLIDE®
(fenofibrate) tablets, which is indicated as an adjunct to diet to
reduce high cholesterol.
Santarus has a diverse product development pipeline. In December 2011,
the company submitted an NDA to the FDA for UCERIS?
(budesonide) tablets for induction of remission of active mild to
moderate ulcerative colitis. The pipeline also includes two late-stage
investigational drugs: RHUCIN® (recombinant human C1
inhibitor) for treatment of acute attacks of hereditary angioedema and
rifamycin SV MMX® for treatment of travelers' diarrhea, both
of which are being evaluated in Phase III clinical studies. In addition,
the company's investigational monoclonal antibody, SAN-300, is being
evaluated in a Phase I clinical program. More information about Santarus
is available at www.santarus.com.
Santarus cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements. The inclusion of forward-looking statements should
not be regarded as a representation by Santarus that any of its plans
will be achieved. Actual results may differ materially from those
set forth in this release due to the risks and uncertainties inherent in
Santarus' business, including, without limitation: difficulties or
delays in development, testing, manufacturing and marketing of, and
obtaining and maintaining regulatory approvals for, Santarus' products;
and other risks detailed in Santarus' prior press releases as well as in
public periodic filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Santarus undertakes no obligation to revise or
update this news release to reflect events or circumstances after the
date hereof. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation Reform
Act of 1995.
Santarus®, FENOGLIDE®
and UCERIS? are trademarks of Santarus, Inc.
GLUMETZA® is a trademark of Biovail
Laboratories International S.r.l. licensed exclusively in the United
States to Depomed, Inc. CYCLOSET® is a
trademark of VeroScience LLC. MMX® is a
trademark of Cosmo Technologies Limited. RHUCIN®
is a trademark of Pharming Group NV.
COMPANY CONTACT:
Santarus, Inc.
Martha L. Hough
VP
Finance & Investor Relations
858-314-5824
Debra P. Crawford
Chief
Financial Officer
858-314-5708
or
INVESTOR CONTACT:
LHA
Jody
Cain (jcain@lhai.com)
Bruce
Voss (bvoss@lhai.com)
310-691-7100
@LHA_IR_PR
© Business Wire 2012
Recommend :
